|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
adults
children aged 5 and older
self-injection (subcutaneous)
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AA26
|
|
gptkbp:CASNumber
|
356547-88-1
|
|
gptkbp:contraindication
|
hypersensitivity to belimumab
|
|
gptkbp:cost
|
high
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
|
|
gptkbp:form
|
lyophilized powder
pre-filled syringe
|
|
gptkbp:genericName
|
gptkb:belimumab
|
|
gptkbp:halfLife
|
19 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Benlysta
|
|
gptkbp:indication
|
autoimmune diseases
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
IgG1-lambda
|
|
gptkbp:manufacturer
|
GlaxoSmithKline
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
B-lymphocyte stimulator (BLyS) inhibitor
|
|
gptkbp:MedlinePlusID
|
a611005
|
|
gptkbp:monitors
|
gptkb:physician
|
|
gptkbp:notRecommendedFor
|
severe active central nervous system lupus
severe active lupus nephritis (prior to 2020)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
active, autoantibody-positive SLE
|
|
gptkbp:PubChem_CID
|
CHEMBL1201836
DB08879
|
|
gptkbp:riskFactor
|
gptkb:depression
suicidal ideation
hypersensitivity reactions
serious infections
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
fever
nausea
diarrhea
infections
infusion reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target
|
BLyS protein
|
|
gptkbp:UNII
|
Q1J0XQ4FZH
|
|
gptkbp:usedFor
|
gptkb:systemic_lupus_erythematosus
lupus nephritis
|
|
gptkbp:bfsParent
|
gptkb:Human_Genome_Sciences
|
|
gptkbp:bfsLayer
|
7
|